DECIBEL CANNABIS CO INC (DB.CA) Stock Fundamental Analysis
Canada - TSX Venture Exchange - TSX-V:DB - CA2434371001 - Common Stock
0.105 CAD
0 (0%)
We assign a fundamental rating of 4 out of 10 to DB. DB was compared to 32 industry peers in the Pharmaceuticals industry. While DB is still in line with the averages on profitability rating, there are concerns on its financial health. DB is growing strongly while it is still valued neutral. This is a good combination!
1. Profitability
1.1 Basic Checks
DB had negative earnings in the past year.
In the past year DB had a positive cash flow from operations.
The reported net income has been mixed in the past 5 years: DB reported negative net income in multiple years.
The reported operating cash flow has been mixed in the past 5 years: DB reported negative operating cash flow in multiple years.
1.2 Ratios
Looking at the Return On Assets, with a value of 7.97%, DB belongs to the top of the industry, outperforming 90.63% of the companies in the same industry.
DB has a Return On Equity of 18.35%. This is amongst the best in the industry. DB outperforms 93.75% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 7.97% | ||
| ROE | 18.35% | ||
| ROIC | N/A |
ROA(3y)0.61%
ROA(5y)-1.43%
ROE(3y)0.45%
ROE(5y)-4.55%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
DB has a better Profit Margin (10.67%) than 84.38% of its industry peers.
In the last couple of years the Profit Margin of DB has grown nicely.
DB has a Gross Margin of 21.98%. This is in the lower half of the industry: DB underperforms 68.75% of its industry peers.
DB's Gross Margin has declined in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | 10.67% | ||
| GM | 21.98% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3Y45.46%
PM growth 5YN/A
GM growth 3Y72.19%
GM growth 5Y-2.05%
2. Health
2.1 Basic Checks
DB does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for DB has been increased compared to 1 year ago.
DB has more shares outstanding than it did 5 years ago.
The debt/assets ratio for DB has been reduced compared to a year ago.
2.2 Solvency
Based on the Altman-Z score of 0.96, we must say that DB is in the distress zone and has some risk of bankruptcy.
Looking at the Altman-Z score, with a value of 0.96, DB is in the better half of the industry, outperforming 65.63% of the companies in the same industry.
The Debt to FCF ratio of DB is 18.67, which is on the high side as it means it would take DB, 18.67 years of fcf income to pay off all of its debts.
DB's Debt to FCF ratio of 18.67 is fine compared to the rest of the industry. DB outperforms 68.75% of its industry peers.
A Debt/Equity ratio of 0.54 indicates that DB is somewhat dependend on debt financing.
Looking at the Debt to Equity ratio, with a value of 0.54, DB is doing worse than 65.63% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.54 | ||
| Debt/FCF | 18.67 | ||
| Altman-Z | 0.96 |
ROIC/WACCN/A
WACC7.94%
2.3 Liquidity
DB has a Current Ratio of 1.34. This is a normal value and indicates that DB is financially healthy and should not expect problems in meeting its short term obligations.
Looking at the Current ratio, with a value of 1.34, DB is in line with its industry, outperforming 40.63% of the companies in the same industry.
A Quick Ratio of 0.61 indicates that DB may have some problems paying its short term obligations.
DB has a Quick ratio of 0.61. This is amonst the worse of the industry: DB underperforms 81.25% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.34 | ||
| Quick Ratio | 0.61 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an impressive 816.22% over the past year.
DB shows a strong growth in Earnings Per Share. Measured over the last years, the EPS has been growing by 90.70% yearly.
The Revenue has grown by 15.11% in the past year. This is quite good.
Measured over the past years, DB shows a very strong growth in Revenue. The Revenue has been growing by 71.51% on average per year.
EPS 1Y (TTM)816.22%
EPS 3Y90.7%
EPS 5YN/A
EPS Q2Q%0%
Revenue 1Y (TTM)15.11%
Revenue growth 3Y20.83%
Revenue growth 5Y71.51%
Sales Q2Q%36.51%
3.2 Future
Based on estimates for the next years, DB will show a very strong growth in Earnings Per Share. The EPS will grow by 77.26% on average per year.
DB is expected to show quite a strong growth in Revenue. In the coming years, the Revenue will grow by 10.75% yearly.
EPS Next Y151%
EPS Next 2Y109.28%
EPS Next 3Y77.26%
EPS Next 5YN/A
Revenue Next Year25.36%
Revenue Next 2Y22.27%
Revenue Next 3Y19.18%
Revenue Next 5Y10.75%
3.3 Evolution
When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is stable.
The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
4. Valuation
4.1 Price/Earnings Ratio
Based on the Price/Forward Earnings ratio of 4.41, the valuation of DB can be described as very cheap.
Based on the Price/Forward Earnings ratio, DB is valued cheaper than 96.88% of the companies in the same industry.
DB is valuated cheaply when we compare the Price/Forward Earnings ratio to 23.93, which is the current average of the S&P500 Index.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | 4.41 |
4.2 Price Multiples
Based on the Price/Free Cash Flow ratio, DB is valued a bit cheaper than the industry average as 65.63% of the companies are valued more expensively.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 24.71 | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
DB's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
DB's earnings are expected to grow with 77.26% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y109.28%
EPS Next 3Y77.26%
5. Dividend
5.1 Amount
DB does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
TSX-V:DB (12/23/2025, 7:00:00 PM)
0.105
0 (0%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)
Earnings (Next)
Inst OwnersN/A
Inst Owner ChangeN/A
Ins Owners5.84%
Ins Owner ChangeN/A
Market Cap60.57M
Revenue(TTM)109.31M
Net Income(TTM)11.66M
Analysts82
Price Target0.27 (157.14%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)1
Avg Revenue beat(2)2.87%
Min Revenue beat(2)-2.22%
Max Revenue beat(2)7.97%
Revenue beat(4)1
Avg Revenue beat(4)-3.1%
Min Revenue beat(4)-13.84%
Max Revenue beat(4)7.97%
Revenue beat(8)2
Avg Revenue beat(8)-5.36%
Revenue beat(12)5
Avg Revenue beat(12)1.08%
Revenue beat(16)5
Avg Revenue beat(16)-1.07%
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)-50%
EPS NQ rev (3m)-50%
EPS NY rev (1m)-60%
EPS NY rev (3m)-62.49%
Revenue NQ rev (1m)-8.96%
Revenue NQ rev (3m)-8.96%
Revenue NY rev (1m)-2.52%
Revenue NY rev (3m)-2.52%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | 4.41 | ||
| P/S | 0.55 | ||
| P/FCF | 24.71 | ||
| P/OCF | 15.31 | ||
| P/B | 0.95 | ||
| P/tB | 0.96 | ||
| EV/EBITDA | N/A |
EPS(TTM)0
EYN/A
EPS(NY)0.02
Fwd EY22.66%
FCF(TTM)0
FCFY4.05%
OCF(TTM)0.01
OCFY6.53%
SpS0.19
BVpS0.11
TBVpS0.11
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 7.97% | ||
| ROE | 18.35% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | 10.67% | ||
| GM | 21.98% | ||
| FCFM | 2.24% |
ROA(3y)0.61%
ROA(5y)-1.43%
ROE(3y)0.45%
ROE(5y)-4.55%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3Y45.46%
PM growth 5YN/A
GM growth 3Y72.19%
GM growth 5Y-2.05%
F-Score6
Asset Turnover0.75
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.54 | ||
| Debt/FCF | 18.67 | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | 23.63% | ||
| Cap/Sales | 1.38% | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | 21.01% | ||
| Current Ratio | 1.34 | ||
| Quick Ratio | 0.61 | ||
| Altman-Z | 0.96 |
F-Score6
WACC7.94%
ROIC/WACCN/A
Cap/Depr(3y)70.46%
Cap/Depr(5y)95.47%
Cap/Sales(3y)2.65%
Cap/Sales(5y)5.7%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)816.22%
EPS 3Y90.7%
EPS 5YN/A
EPS Q2Q%0%
EPS Next Y151%
EPS Next 2Y109.28%
EPS Next 3Y77.26%
EPS Next 5YN/A
Revenue 1Y (TTM)15.11%
Revenue growth 3Y20.83%
Revenue growth 5Y71.51%
Sales Q2Q%36.51%
Revenue Next Year25.36%
Revenue Next 2Y22.27%
Revenue Next 3Y19.18%
Revenue Next 5Y10.75%
EBIT growth 1Y-65.62%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year310.35%
EBIT Next 3Y86.3%
EBIT Next 5Y47.14%
FCF growth 1Y-16.46%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-21.82%
OCF growth 3YN/A
OCF growth 5YN/A
DECIBEL CANNABIS CO INC / DB.CA FAQ
What is the ChartMill fundamental rating of DECIBEL CANNABIS CO INC (DB.CA) stock?
ChartMill assigns a fundamental rating of 4 / 10 to DB.CA.
Can you provide the valuation status for DECIBEL CANNABIS CO INC?
ChartMill assigns a valuation rating of 5 / 10 to DECIBEL CANNABIS CO INC (DB.CA). This can be considered as Fairly Valued.
Can you provide the profitability details for DECIBEL CANNABIS CO INC?
DECIBEL CANNABIS CO INC (DB.CA) has a profitability rating of 4 / 10.